Introduction
Glucocorticoids (GC) induce apoptosis in immature lymphocytes and various malignancies of lymphoid origin (Evans-Storms and Cidlowski, 1995; Thompson, 1994) , which has led to their extensive use in the treatment of corresponding leukemias and lymphomas. The molecular mechanisms leading to GC-induced apoptosis and to the clinically-relevant phenomenon of GC resistance in such tumor cells have, however, remained poorly understood. The signal transduction pathway is initiated by binding of GC to its cognate receptor (GR), a ligand-activated transcription factor of the Zn ®nger type (Evans, 1988; Hollenberg and Evans, 1988) . The GR may transmit the death signal through gene transactivation (Schwartzman and Cidlowski, 1994; Chapman et al., 1996) , repression of gene expression (Helmberg et al., 1995) , or perhaps both mechanisms. The GC down-or upregulated genes that actually mediate the`private pathway' of this death response are not known. A set of GC-regulated candidate genes has been identi®ed by various approaches (reviewed in Geley et al., 1996a) , including the GC-repressed c-myc (Thulasi et al., 1993) and the GC-induced c-jun (Zhou and Thompson, 1996) genes, but their precise role, if any, in GC-induced apoptosis needs to be established. Concerning the execution phase (`common pathway'), GC-triggered cell death is associated with caspase activation (Neamati et al., 1995; Zhivotovsky et al., 1995; Geley et al., 1997b; Robertson et al., 1997) , as are most forms of apoptosis. The respective caspases have not yet been suciently identi®ed, but may dier from those mediating other cell death forms, particularly CD95/Fas/Apo-1-induced apoptosis: Caspases sensitive to the cowpox virus protease inhibitor crmA, like caspase 8/FLICE and caspase 1/ICE (Zhou et al., 1997) , may not play a critical role (Geley et al., 1997b; Memon et al., 1995) , while baculovirus p35-sensitive caspases, including the typical`eector caspases ' (Thornberry et al., 1997) , apparently do (Robertson et al., 1997) .
Regarding mechanisms of resistance to GC-induced apoptosis, the presence of functional GR in sucient amounts is an absolute requirement and leukemia cells that express GR with loss-of-function mutations (Strasser-Wozak et al., 1995; Hala et al., 1996; Ashraf and Thompson, 1993; Powers et al., 1993) or insucient expression of functional GR (Geley et al., 1996b) are resistant to GC-induced apoptosis. Further downstream mechanisms for GC resistance have not been clearly identi®ed, perhaps because of the limited knowledge of the corresponding signaling cascade. One attractive possibility includes over-expression of anti-apoptotic proteins, such as Bcl-2, a suggestion corroborated by this molecule's reported inhibition of GC-induced apoptosis (Lam et al., 1994; Reed, 1992, 1993; Alnemri et al., 1992; Caron-Leslie et al., 1994; Memon et al., 1995; Moreno et al., 1996; Miyashita et al., 1997; Brunet et al., 1998; . Bcl-2 has been isolated as an oncogene recurrently translocated in certain B-cell lymphomas (Tsujimoto et al., 1985; Bakhshi et al., 1985) . Its role as anti-apoptotic protein has been identi®ed by its homology to the C. elegans survival gene, ced-9 (Hengartner and Horvitz, 1994) , as well as by analyses of mice transgenic for bcl-2 (Sentman et al., 1991; Strasser et al., 1991) . Subsequently, Bcl-2 has been shown to be the prototype of a structurally related family of apoptosis-promoting and -preventing proteins whose balance might be critical for cell survival (Oltvai and Korsmeyer, 1994; Cory, 1995) . Bcl-2 prevents caspase activation and apoptosis in several (Boulakia et al., 1996; Chinnaiyan et al., 1996; Monney et al., 1996; Messmer et al., 1996; Smyth et al., 1996; Shimizu et al., 1996; Armstrong et al., 1996; Melkova et al., 1997; Mandal et al., 1996; Ibrado et al., 1996; Brunet et al., 1998) , although not all (Chinnaiyan et al., 1996; , systems. Since Bcl-2 and its antagonist Bax are potential pore-forming proteins (Minn et al., 1997; Schendel et al., 1997; Antonsson et al., 1997) , Bcl-2 might interfere with the mitochondrial release of APAF-2 (apoptosis protease-activating factor 2)/cytochrome c (Kluck et al., 1997; Yang et al., 1997; Kharbanda et al., 1997) and/or other apoptosis-inducing factors (Susin et al., 1996; Decaudin et al., 1997) , that may trigger the caspase cascade. Alternatively, or in addition, Bcl-2 may bind to, and inhibit, APAF-1, the recently cloned ced-4 homologue (Zou et al., 1997) , or may act via other, as yet unknown, mechanisms.
The present study investigates possible Bcl-2 eects on cell death and other GC-induced phenomena in the widely used human T-cell acute lymphoblastic leukemia model CCRF-CEM (Norman and Thompson, 1977) , and attempts to position Bcl-2 in the GCinduced death pathway by exploiting stably-transfected CCRF ± CEM derivatives that express human bcl-2 from a tetracycline-responsive promoter.
Results

Establishment of CEM-C7H2 sublines with regulated Bcl-2 expression
To study the eects of Bcl-2 on GC-induced apoptosis in CEM leukemia cells, we generated stably-transfected CEM-C7H2 subclones that allowed tetracycline-regulated expression of transgenic Bcl-2. For this purpose, we ®rst produced CEM-C7H2 subclones stably expressing the tetracycline-controllable synthetic transcription factor, tTA, from the human elongation factor-1 promoter. Out of these subclones, we selected one that showed signi®cant (40 ± 200-fold) induction of a tet operon-driven luciferase reporter gene upon withdrawal of doxycycline. This subclone, termed CEM-C7H2 pEFtTA -2A10, was subsequently stably transfected with the tet operon-driven human bcl-2 cDNA construct, ptetBcl-2, along with the pKS-tkHyg selection plasmid. Three subclones, termed CEM-C7H2 tetBcl2 -9C3, 9F3 and 10E1, that showed dramatic doxycycline-regulated expression of exogenous Bcl-2 (Figure 1 ), were used for further analyses. Endogenous Bcl-2 was not detected by Northern analyses in any of the above CEM derivatives including the parental CEM-C7H2 and C7H2-2A10 cell lines (data not shown).
Induction of exogenous bcl-2 gene expression delays, but does not prevent, GC-induced apoptosis
To assess the eect of exogenous Bcl-2 on GC-induced apoptosis in CEM-C7H2 leukemia cells, we cultured the above stably-transfected CEM-C7H2 subclones in the absence or presence of 10 77 M dexamethasone for various time periods. One set of cells was treated with doxycycline which has been shown to completely repress the transfected Bcl-2 cDNA construct ( Figure  1 ), and the other set was cultured in the absence of doxycycline, which leads to strong expression of exogenous Bcl-2 in the transfected cells. After 24, 36, 48, 72 and 96 h, degree of apoptosis was determined by FACS analyses (Figure 2 ). The parental CEM-C7H2-2A10 subline (stably transfected with the tTA plasmid) and the Bcl-2 transfected subclones cultured in the presence of doxycycline (`Bcl-2 o') underwent similarly high degrees of GC-induced apoptosis after 48 h and thereafter. Apoptosis was markedly reduced in the absence of doxycycline (`Bcl-2 on') in the transfected subclones at 36 and 48 h. However, when the cells were maintained in the presence of GC for 72 ± 96 h, the protective eect of exogenous Bcl-2 expression was abrogated. 
CEM-C7H2
pEFtTA -2A10 subclones 10E1, 9C3, and 9F3 (stably transfected with tet operator-driven human Bcl-2 cDNA construct ptetBcl-2) were cultured in the absence or presence of 100 ng/ml doxycycline (Doxy) and the cells were subjected to Northern blot analysis with 32 P-labeled cDNA probes for human bcl-2 and, after removal of the probe, chicken GAPDH. Shown is the 1.9 kb mRNA corresponding to the transfected human Bcl-2 cDNA, the much larger endogenous Bcl-2 transcript was not detectably expressed in these or the parental CEM-C7H2 and C7H2-2A10 cell lines (data not shown) Figure 2 Expression of transgenic Bcl-2 delays, but does not prevent, GC-induced apoptosis. The parental C7H2 pEFtTA -2A10 control line and its subclones 10E1, 9C3 and 9F3 were cultured in medium containing 10 77 M dexamethasone in the presence or absence of 100 ng/ml doxycycline for the indicated times and subjected to apoptosis determination. Shown are the results of a representative experiment. For clarity, the data obtained with the three subclones were pooled (labeled 2A10
Bcl-2 in the Figure) and are presented as means+standard deviation. Similar results were obtained in several other comparable experiments Bcl-2 interferes with GC-induced apoptosis-associated PARP cleavage and eector caspase activation GC-induced apoptosis in CEM cells is closely associated with cleavage of PARP (Geley et al., 1997b; Brunet et al., 1998; Benson et al., 1998) , a typical target of`eector caspases', such as CPP32/ caspase-3 (Thornberry et al., 1997). To determine whether Bcl-2 exerts its protective eect (seen up to 48 h) upstream or downstream of PARP cleavage, we analysed PARP expression during GC treatment in CEM-C7H2 cells and transfected subclones in the presence (exogenous Bcl-2 o) and absence (exogenous Bcl-2 on) of doxycycline. As exempli®ed in Figure 3a , withdrawal of doxycycline (i.e., induction of exogenous Bcl-2) prevented cleavage of the 113 kD PARP molecule into the 89 kD fragment typical for GCinduced apoptosis (Geley et al., 1997b; Robertson et al., 1997) . Thus, in this human leukemia model, like in many other systems (Boulakia et al., 1996; Chinnaiyan et al., 1996; Monney et al., 1996; Messmer et al., 1996; Smyth et al., 1996; Shimizu et al., 1996; Armstrong et al., 1996; Melkova et al., 1997; Mandal et al., 1996; Ibrado et al., 1996) , Bcl-2 acted upstream of caspasemediated PARP cleavage. However, when the exogenous Bcl-2 expressing cell lines were cultured in the continuous presence of GC for longer periods (which leads to apoptosis, see Figure 2 ), PARP cleavage was observed (Figure 3a) . In agreement with, and extension of, the PARP Western data, occurrence of eector caspase activity determined by DEVDase assays was similarly delayed by exogenous Bcl-2 expression for about 24 h (Figure 3b ).
Bcl-2 does not aect GC-induced inhibition of proliferation
GC-induced apoptosis in CEM cells is preceded by a marked reduction in cell proliferation, as shown by [ 3 H] thymidine uptake assays (Figure 4 ). Since the antileukemic eect of GC may result from both apoptosis induction and inhibition of proliferation, we wondered whether Bcl-2 aected GC-induced proliferation arrest. As shown in Figure 4 , induction of Bcl-2 expression by doxycycline withdrawal in stably-transfected CEM-C7H2 cells had only marginal, if any, eect on GCinduced growth arrest. Hence, Bcl-2 clearly acted downstream of GC-regulated events leading to inhibition of cell cycle progression.
GC-induced apoptosis is preceded by reduction in the steady state levels of several mRNA species, a phenomenon not aected by Bcl-2
To identify possible causes for the failure of Bcl-2 to prevent cell death in the continuous presence of GC, we determined its expression during GC treatment. Total RNA recovered from untreated cells and cells treated with GC for 24, 36 and 48 h in the absence or presence of doxycycline was analysed for expression of Bcl-2 mRNA. c-myc, known to be downregulated during GC-treatment (Yuh and Thompson, 1989; Thulasi et al., 1993) , and the`house-keeping' genes, a-tubulin and GAPDH, were used as controls. As expected from Figure 1 , the corresponding Northern analyses ( Figure 5) showed doxycycline-regulated expression of the transfected bcl-2 mRNA in all instances, as well as the reported c-myc downregulation by GC (Yuh and Thompson, 1989) . Unexpectedly, however, a marked reduction of steady state mRNA levels of both the transgenic Bcl-2 and the 2`housekeeping' genes was observed during GC treatment. 77 M dexamethasone (Dex) and/or 100 ng/ml doxycycline (Doxy). Subsequently, the cells were lysed, incubated with the chromogenic Ac-DEVD-paranitroanilide substrate, and absorption determined as a parameter for DEVDase activity. Shown are the results of a representative experiment performed in triplicate. For clarity, the data obtained with the three subclones were pooled (labeled 2A10 Bcl-2 in the Figure) and are presented as means+standard deviation. Similar results were obtained in two other experiments This downregulation became detectable between 24 and 36 h and preceded apoptosis as documented best in Bcl-2 expressing cells where apoptosis is delayed (compare 9F3 lane 1 with lanes 5 and 7). In 2A10 cells and in 9F3 cells treated with doxycycline, the occurrence of high levels of apoptosis at 48 h (see Figure 2 ) somewhat obscured the GC eect because it reduced the yield of RNA as re¯ected in the ethidium bromide stains for 9F3 lane 8 and 2A10 lanes 7 and 8. Importantly, however, the reduction of mRNA levels was not prevented by the expression of transgenic Bcl-2. Since it included reduction of transgenic Bcl-2 mRNA, it might explain the inability of Bcl-2 to prevent GC-induced cell death in the continuous presence of the hormone.
Discussion
There is considerable interest in the potential role of the anti-apoptotic Bcl-2 protein in GC-induced leukemia apoptosis and resistance to this phenomenon. In agreement with studies in Bcl-2 transgenic mice (Strasser et al., 1991; Sentman et al., 1991) , several groups have reported prevention of GC-induced leukemia apoptosis by Bcl-2 (Lam et al., 1994; Reed, 1992, 1993; Alnemri et al., 1992; Caron-Leslie et al., 1994; Memon et al., 1995; Moreno et al., 1996; Miyashita et al., 1997; Brunet et al., 1998; Benson et al., 1998) . However, these studies, including those with mouse models, failed to show a protective eect over extended time periods and/or in the continuous presence of GC. The latter may, however, be important in the in vivo situation where GC can be continuously present for extended periods of time. Since Bcl-2 does not markedly in¯uence the anti-proliferative eect of GC, and does not protect the cells from ultimate death (presumably due to its failure to prevent GC-mediated downregulation of multiple mRNAs, including its own), it appears questionable whether Bcl-2 overexpression may account for GC resistance in vivo.
Regarding the site of action of Bcl-2 in the GCinduced death pathway, the observed inhibition of PARP cleavage and DEVDase activity by Bcl-2 up to 48 h is in good agreement with numerous reports placing Bcl-2 upstream of the activation of at least some`eector' caspases (Boulakia et al., 1996; Chinnaiyan et al., 1996; Monney et al., 1996; Messmer et al., 1996; Smyth et al., 1996; Shimizu et al., 1996; Armstrong et al., 1996; Melkova et al., 1997; Mandal et al., 1996; Ibrado et al., 1996; Brunet et al., 1998; Adelman et al., 1983; Morimoto and Schlossman, 1985) . By mechanisms brie¯y outlined in the Introduction, Bcl-2 may prevent a putative GC-induced death signal to release caspase activating factors from the mitochondria, thereby initiating the terminal`common' eector phase of the death pathway. In support of this concept, Bcl-2 prevented the loss of mitochondrial membrane potential that typically precedes GCinduced apoptosis in CCRF-CEM and other cells (Zamzami et al., 1995; Decaudin et al., 1997; Susin et al., 1997) . Recently, however, a novel mechanism of Bcl-2 action in GC-induced apoptosis has been proposed that placed bcl-2 at the top of the GCmediated death pathway (Miyashita et al., 1997) . Based 77 M dexamethasone and/or 10 ng/ml doxycycline for the times indicated. Approximately 10 mg total RNA per lane were fractionated on an agarose gel, transferred to a nitrocellulose ®lter and sequentially hybridized to 32 P-labeled cDNA probes for bcl-2, c-myc, atubulin or GAPDH. Between hybridizations, the ®lter was stripped with boiling 0.16SSC/0.1%SDS. The insert underneath the autoradiographs shows an ethidium bromide stain of one tenth of the RNA used for the above Northern analysis and separated on a non-denaturing agarose gel. The bottom panels show the results obtained with the`house keeping' probes on a separate Northern blot using RNA from the parental CEM-C7H2 pEFtTA -2A10 control line Tetracycline-regulated Bcl-2 in human T-ALL lines BL Hartmann et al on transient transfection experiments with AP-1 responsive reporters, it was suggested that Bcl-2 interfered with the transrepressive function of the activated GR thereby preventing GC-induced apoptosis. Our data disagree with this notion because Bcl-2 did not prevent the dramatic downregulation of several cellular mRNAs in our system, suggesting that the above transient episomal expression assays may not properly re¯ect the regulation of chromosomal genes. It seems more likely that Bcl-2 does not aect thè private' pathway to GC-induced cell death, a notion upheld by the fact that another impressive GCregulated event, inhibition of proliferation, was not markedly aected by Bcl-2 in our, the above (Miyashita et al., 1997) , or several other (Caron-Leslie et al., 1994; Alnemri et al., 1992; Miyashita and Reed, 1993) systems of GC-induced apoptosis. Whether GC-regulated growth inhibition and/or reduction of mRNA levels are unrelated epiphenomena or components of the`private' portion of death signaling cascade, and how these two events are triggered by GC on a molecular level, is presently not known. G1 growth arrest has been shown to be unrelated to, or even protect from, apoptosis in most systems of p53-mediated apoptosis (Brugarolas et al., 1995; Deng et al., 1995; Gorospe et al., 1997) . In this instance, growth arrest occurred via induction of p21/ WAF1. Interestingly, in multiple myeloma cells, dexamethasone also mediated growth arrest through p21/WAF1 induction (Urashima et al., 1997) . This does, however, not seem to be the case in CCRF-CEM cells, where dexamethasone did not induce p21/WAF1 mRNA (S Geley, unpublished results), while transfection with functional p53 did (Geley et al., 1997a) . At any rate, while proliferation arrest may not be a good candidate for the triggering event in GC-induced apoptosis, mRNA suppression may well account for cell death, since CCRF-CEM cells are highly sensitive to RNA synthesis inhibitors, like actinomycin D, aamanitin and cordycepin (S Geley, unpublished results). Whether either one of these events is, indeed, the trigger for the execution phase of GC-induced apoptosis and how the two relate to each other is currently being investigated in our laboratory.
Materials and methods
Cell lines, cell culture and reagents CEM-C7H2 (Strasser-Wozak et al., 1995) is a highly GCsensitive subclone of CCRF-CEM-C7 (Norman and Thompson, 1977) . It was used to generate all stably transfected cells described below. All cell lines were grown in RPMI 1640 supplemented with 5 ± 10% fetal calf serum (HyClone, Logan, UT, USA), 100 U/ml penicillin, 100 mg/ ml streptomycin and 2 mM L-glutamine at 378C and 5% CO 2 . All reagents were from Sigma (Vienna, Austria), unless otherwise indicated.
Plasmid constructs and stable transfections
Plasmids pBK-KS-hBcl-2 (Seto et al., 1988) and pUHC13-3, pUHD10-3, pUHD13-6 and pUHD15-1 (Gossen and Bujard, 1992) were generously donated by Drs Korsemeyer (pKS-hBcl-2) and Bujard (all others). pEF-1-Neo is a plasmid containing a human elongation factor 1 promoter and a neomycin resistance gene driven by the SV40 early promoter (generously donated by Dr Baier). pEFtTA was produced by introducing the EcoRI/HindIII fragment of pUHD15.1, containing the tTA and SV40 poly A sequences, into the EcoRI/SpeI sites of pEF-1-Neo by partial ®ll-in of the HindIII and SpeI ends. This brought the tTA coding sequence under the control of the human elongation factor 1 promoter. Plasmid ptetBcl-2 was generated by cloning the 1.9 kb EcoRI bcl-2 cDNA fragment from pBK-KS-hBcl-2 into the EcoRI site of pUHD10-3. pKS-tkHyg is a selection plasmid with a relatively weak promoter to avoid simultaneous constitutive transactivation of the possibly co-integrated tetracycline-responsive plasmid ptetBcl-2. It was constructed in our lab by inserting a HindIII ± NsiI fragment containing the hygromycin B phosphotransferase gene, along with the minimal tk promoter (from plasmid p3' SS, Stratagene, La Jolla, CA, USA), into the HindIII ± PstI sites of pBluescriptII-KS 7 (Stratagene, La Jolla, CA, USA). Stable transfections were performed as previously described (Geley et al., 1997a) . To generate subclones with constitutive tTA expression, logarithmically-growing CEM-C7H2 cells (Strasser-Wozak et al., 1995) were transfected with ScaIlinearized pEFtTA by electroporation and stably transfected cells selected with 1 mg/ml G418 (bioactivity 70%, GIBCO ± BRL Life Technologies, Eggenstein, Germany). To generate subclones with tetracycline-regulated bcl-2 expression, one of the pEFtTA-transfected subclones (C7H2 pEFtTA -2A10, selected on the basis of regulation a tTA-responsive reporter construct in a transient luciferase assay), was transfected with 20 mg pvuI-linearized ptetBcl-2 together with 10 mg uncut pKStkHyg by electroporation. Stably transfected cells were selected with 1 mg/ml G418 and 0.25 mg/ml hygromycin B (Boehringer Mannheim, Vienna, Austria).
Determination of proliferation and apoptosis
Degree of proliferation (Strasser-Wozak et al., 1995) and percentage of apoptotic cells (Geley et al., 1997a) were determined as previously detailed. Brie¯y, for determination of proliferation, cell aliquots were incubated in triplicate with [ 3 H]-thymidine for a 6 h pulse, and the uptake counted by liquid scintillation. For detection and quanti®cation of apoptosis, nuclear staining with propidium iodide in concert with forward/sideward scatter analysis (Nicoletti et al., 1991) was used. Brie¯y, cells were stained with fresh propidium iodide in 0.1% Triton X-100/0.1% sodium citrate and the nuclei were subjected to apoptosis analysis in a FACScan (Becton Dickinson, San Jose, CA, USA) using forward/sideward scatter and uorescence intensity as parameters. Cell debris and small particles were excluded from further analyses based on forward/sideward scatter criteria, as described (Sgonc and Wick, 1994) . Based on propidium iodide staining, nuclei in the sub-G1 marker window were considered to represent apoptotic cells.
DEVDase assay
To detect the activity of enzymes cleaving the eector caspase recognition sequence DEVD, 5610 6 cells were resuspended in 100 ml caspase buer (20 mM PIPES, 100 mM NaCl, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, pH 7.2) (Stennicke and Salvesen, 1997) containing 10 mM sodium¯uoride, 1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ ml leupeptin, 0.68 mg/ml pepstatin and 10 mM dithiothreitol, lysed by two freeze/thaw cycles, and centrifuged at 16 000 g at 48C for 15 min. Fifty mg protein, as determined by the Bradford technique, were incubated with 100 mM of the chromogenic Ac-DEVD-para-nitroanilide (Bachem, Bubendorf, Switzerland) at 378C for 30 min and the resulting absorption measured by 405 nM in a Hitachi U-2000 spectrophotometer (Hitachi, Vienna, Austria).
Immunoblot analyses
PARP cleavage was detected by a polyclonal goat antiserum to human PARP as has been detailed (Geley et al., 1997b) and by a monoclonal antibody as outlined below. Whole cell lysates were separated on denaturing polyacrylamide gels, transferred to nitrocellulose and incubated with a monoclonal mouse antibody against bovine PARP (clone C2-10, Pharmingen, Hamburg, Germany), followed by horseradish peroxidase-labeled secondary antibodies. Peroxidase activity was detected by chemiluminescence reaction with ECL Western blotting detection reagent according to the manufacturer (Amersham Life Sciences, Buckinghamshire, UK).
Northern blot analysis
Total RNA was extracted by a single-step procedure, fractionated on formaldehyde-agarose gels, blotted onto nitrocellulose membranes and baked at 808C. The ®lters were prehybridized to block unspeci®c binding and hybridized to heat-denatured 32 P-labeled cDNA probes for human bcl-2 (donated by Dr SJ Korsmeyer) (Seto et al., 1988) , human c-myc (gift from Dr M Eilers) (Eilers et al., 1989) , chicken GAPDH (Dugaiczyk et al., 1983) , or human a-tubulin (donated by Dr A Helmberg) (Cowan et al., 1983) , respectively. The washed blots were exposed to an Agfa Curix X-ray ®lm with an amplifying screen at 7908C for 3 h to several days. Between hybridizations, identical blots were stripped by boiling in 0.1% SDS/0.16SSC.
